In the field of in situ regeneration of soft tissue, TransTissue mainly focuses on the repair of mesenchymal tissues. For in situ repair, autologous cells are attracted by bioactive matrices and guided to form repair tissue. In cartilage repair, after trauma or in degenerative diseases, the repair tissue is fibrous, often non-durable, and biomechanically unstable. This is due to the limited self-renewal capacity of articular cartilage.
The 1st generation of tissue engineering cartilage repair involves the injection of an autologous cell suspension, known as “autologous chondrocyte implantation” (ACI).
The 2nd generation of cartilage repair is represented by the implantation of chondrocytes in matrices as well as stable 3D grafts or osteochondral transplants. Second generation cartilage transplants are robust and easy for surgeons to handle, and significantly improve the healing of cartilage defects. The second generation BioSeed®-C graft is manufactured and distributed by BioTissue.
The 3rd generation of tissue engineering cartilage repair takes advantage of the in vivo regeneration and guided tissue repair. TransTissue therefore developed a cell-free cartilage therapy based on mesenchymal stem and progenitor cells that are recruited to cartilage defects and subsequently guided to regenerate articular cartilage. This cell-free product “chondrotissue®” has achieved the CE mark of conformity and is used for cartilage defects of synovial joints.